Targeting the SARS-CoV‑2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders

High Resolution Image Download MS PowerPoint Slide COVID-19 is a global pandemic, thus requiring multiple strategies to develop modalities against it. Herein, we designed multiple bioactive small molecules that target a functional structure within the SARS-CoV-2’s RNA genome, the causative agent of COVID-19. An analysis to characterize the structure of the RNA genome provided a revised model of the SARS-CoV-2 frameshifting element, in particular its attenuator hairpin. By studying an RNA-focused small molecule collection, we identified a drug-like small molecule ( C5 ) that avidly binds to the revised attenuator hairpin structure with a K d of 11 nM. The compound stabilizes the hairpin’s folded state and impairs frameshifting in cells. The ligand was further elaborated into a ribonuclease targeting chimera (RIBOTAC) to recruit a cellular ribonuclease to destroy the viral genome ( C5-RIBOTAC ) and into a covalent molecule ( C5-Chem-CLIP ) that validated direct target engagement and demonstrated its specificity for the viral RNA, as compared to highly expressed host mRNAs. The RIBOTAC lead optimization strategy improved the bioactivity of the compound at least 10-fold. Collectively, these studies demonstrate that the SARS-CoV-2 RNA genome should be considered druggable.

Abstract licence: CC BY

1. 18.

   Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease · 2018

2. 25.

   Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro · 2020

3. 33.

   RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look · 2020

4. 34.

   Structural and functional conservation of the programmed −1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2) · 2020

32 more references, whose wording the paper’s licence keeps private.

• Proteolysis-targeting chimeras (PROTACs) in cancer therapy · 2022

• Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells · 2022

• Restriction of SARS-CoV-2 replication by targeting programmed −1 ribosomal frameshifting · 2021

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.